BC
PHAT icon

Bridgefront Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Bridgefront Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Sell
14,954
-2,027
-12% -$25.6K 0.04% 481
2025
Q4 		$282K Buy
+16,981
New +$243K 0.07% 386

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Bridgefront Capital's PHAT Position: Q1 2026 in Review

Bridgefront Capital reduced its Phathom Pharmaceuticals (PHAT) stake by 12% in Q1 2026, selling an estimated $25.6K and leaving 14,954 shares worth $166K. The position accounts for 0.04% of the portfolio, ranked #481.

Bridgefront Capital first reported a position in PHAT in Q4 2025 and has held it in 2 quarters since. The position peaked at $282K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Bridgefront Capital held 14,954 shares of Phathom Pharmaceuticals worth $166K as of Q1 2026.
  • Bridgefront Capital sold 2,027 Phathom Pharmaceuticals shares in Q1 2026, an estimated $25.6K.
  • Phathom Pharmaceuticals made up 0.04% of Bridgefront Capital's portfolio in Q1 2026, its #481 holding.
  • Bridgefront Capital first reported a position in Phathom Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Bridgefront Capital's Phathom Pharmaceuticals position peaked at $282K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.